A quarterly market intelligence report for medspa owners, physicians, and aesthetics professionals. What moved in Q1, what's coming in Q2, and exactly what you should do about it.
Here's a number that should change how you think about marketing your practice: according to Kantar's 2026 Health & Wellness Report[1], 24% of all healthcare discovery now happens through AI-powered agents — not Google, not Instagram, not word of mouth. One in four potential patients are asking an AI where to go for treatment.
This isn't a prediction. It's already happening. ChatGPT, Google's AI Overviews, Perplexity, and Claude are all serving clinic recommendations in response to queries like "best Botox clinic in Tampa" or "where can I get semaglutide near me." The referral network that built your practice over the last decade is being restructured around algorithms that prioritize structured data, verified credentials, and authoritative backlinks — not paid ads or vanity metrics.
The implications for medspas are concrete. If your clinic's data lives only on your website and your Google Business Profile, you're invisible to the AI layer. Directories that structure clinic data — services offered, credentials verified, compliance status, patient reviews — become the source material that AI agents pull from when recommending providers. This is why being listed on platforms like GlowRoute[2] isn't just a lead-gen play anymore. It's infrastructure for the AI-referral economy.
Meanwhile, 70% of all aesthetic procedure searches are location-based. The "near me" query isn't going away — it's just moving from a search bar to a conversational interface. The clinics that win in Q2 and beyond are the ones whose data is structured, verified, and indexed by both traditional search engines and the AI layer simultaneously.
The global medical aesthetics market hit $20.08 billion in 2025 and is projected to reach $22.41 billion in 2026, growing at a compound annual rate between 12.5% and 15.9% depending on the source. By 2032, the market is expected to nearly double to $44.83 billion. These numbers come from a convergence of reports by Grand View Research[3], Precedence Research[4], and multiple industry analyses cited by the American Med Spa Association (AmSpa)[5].
What's driving it? Three things. First, the normalization of aesthetic procedures across age groups and demographics — Botox is no longer a secret, and GLP-1 weight management has brought an entirely new patient population through medspa doors. Second, the longevity and wellness segment is growing at 25–40% annually, with high-value clients spending $10,000+ per year on peptide therapy, IV infusions, hormone optimization, and regenerative treatments. Third, the shift from one-time procedures to membership-based recurring revenue models is making medspas structurally more valuable.
But growth doesn't mean the rising tide lifts all boats. The same quarter that saw record market projections also delivered 70+ FDA warning letters, a signed state registration law, and the end of legal compounded GLP-1s. The clinics that are growing are the ones operating compliantly, investing in recurring revenue, and staying visible to the patients who are actively searching. The ones that aren't are facing enforcement, margin compression, and the very real risk of being acquired at a discount — or shut down entirely.
Among clinics listed in the GlowRoute directory, those offering membership programs report 2.3x higher patient retention than those operating on a purely transactional model. The data confirms what PE buyers already know: recurring revenue isn't just a valuation driver — it's a survival strategy.
On February 26, 2026, Indiana became the first state to pass comprehensive medspa registration legislation. Senate Bill 282[6] requires every medical spa in the state to register with the state, submit to inspections, and meet new oversight standards. Governor Braun signed it on March 12. It takes effect July 1, 2026, with mandatory registration by January 1, 2027.
Indiana's law is the opening shot. Similar bills are moving through legislative sessions in Iowa, Florida, and Arizona. Georgia has no active bill yet, but multiple industry observers describe the regulatory posture there as "watching closely." The pattern is unmistakable: after years of complaint-driven, largely reactive oversight, states are moving toward proactive registration, inspection, and compliance requirements for medspas.
The politics behind these bills are worth understanding. AmSpa[8] has publicly argued that bills like SB 282 are partly backed by pharmaceutical companies — Eli Lilly[9] and Novo Nordisk[10] specifically — who benefit from restricting compounding pharmacies. The Partnership for Safe Medicines[11], on the other hand, applauded the Indiana bill as overdue consumer protection. Both perspectives have merit. What matters for your practice is that the direction is clear: regulation is tightening, and grace periods are finite.
The numbers tell the story. U.S. spending on GLP-1 receptor agonists grew by more than 500% between 2018 and 2023 — from $13.7 billion to $71.7 billion, according to HHS/ASPE data[12]. Ozempic alone went from $410 million to $26.4 billion. The global semaglutide market is projected to hit $39.37 billion in 2026 and grow to $86 billion by 2034. This is one of the fastest-growing pharmaceutical categories in history, and it has fundamentally reshaped the medspa revenue model.
But the access pathway that fueled much of that growth — compounded semaglutide — is now illegal. The FDA officially removed semaglutide from its drug shortage list[13] in early 2025. Tirzepatide (Mounjaro/Zepbound) was removed in October 2024. The legal basis for compounding either drug has expired. Compounding pharmacies that continue to manufacture and distribute these products face enforcement action.
And enforcement isn't theoretical. On March 3, 2026, the FDA issued 30 warning letters in a single batch[14] to companies selling unapproved semaglutide products. Named companies include Hims & Hers, Lovely Meds, Hello Cake, MEDVi, and 26 others. In total, over 70 telehealth firms have been warned in the past six months, with 30% of those affiliated with medical groups. Primary violations: false "sameness" claims, obscuring non-FDA-approved status, and misleading marketing.
For clinics, the math is straightforward. Brand-name Wegovy and Ozempic cost $900–$1,300/month without insurance. Compounded alternatives were running $200–400. That pricing gap created an enormous market — and now that market is being squeezed. The clinics that survive this transition are the ones offering FDA-approved GLP-1 programs with legitimate prescriptions, named pharmacy suppliers, and documented medical oversight. Grey-market sourcing isn't a growth strategy anymore. It's a countdown to a warning letter.
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr.[15] announced that 14 of 19 previously banned peptides would return to Category 1 status — meaning licensed 503A compounding pharmacies would again be permitted to compound them with a physician's prescription. The announcement came on The Joe Rogan Experience[16], not through the Federal Register.
Three weeks later — as of March 22, 2026 — the FDA has not published a formal updated Category list. No Federal Register notice. No official guidance. The announcement remains a policy statement without formal regulatory implementation. Legal experts interviewed by AmSpa[17] and reported across industry publications estimate formal reclassification will arrive no earlier than Q2 2026.
This matters for a specific reason: clinics that have already begun re-offering these peptides based on the announcement alone are taking real legal risk. Until the FDA formally publishes the updated Category 1 list, the prior Category 2 designations technically remain in effect. Enforcement discretion may protect some providers in the interim — but "enforcement discretion" is not the same as legal authorization.
* Tesamorelin and Zilucoplan have existing FDA-approved brand-name products. Category 2 designation preserves market exclusivity for the manufacturer. Remaining Category 2 peptides lack sufficient safety data for compounding authorization. Source: FDA Bulk Drug Substances Evaluation[18]
In spring 2024, patients across 9 states — including Florida and California — were hospitalized after receiving counterfeit botulinum toxin at medspas. Multiple victims developed systemic botulism, a condition that can cause paralysis and respiratory failure. The CDC launched an investigation[19] that traced the products to unlicensed, unapproved sources distributed outside the legitimate supply chain.
In February and March 2026, the Sun Sentinel published "Med Spas Unmasked,"[20] a three-part investigative series exposing the structural gaps in Florida's medspa oversight. The findings were damning: anyone can own a medspa in Florida. The title "Master Injector" requires less certification than a master plumber. Investigations are triggered by complaints — typically filed after a patient is already harmed. The Florida Department of Health complaint portal[21] remains the primary consumer protection mechanism.
For clinic operators, this isn't just a news cycle — it's a positioning opportunity. Patient search behavior has shifted measurably toward safety queries. "Is my medspa safe," "how to verify Botox is real," and "medspa credentials check" are all emerging search terms with growing volume. Clinics that proactively publish their supply chain, display their physician oversight structure, and earn third-party verification are converting that anxiety into appointments.
Private equity hasn't left medical aesthetics. In fact, the sector remains the strongest-performing healthcare M&A category — driven by cash-pay revenue, recurring demand, and minimal insurance reimbursement complexity. But the era of the 2021–2023 land grab is definitively over. PE buyers in 2026 are methodical, compliance-focused, and deeply allergic to regulatory risk.
February 2026 saw active healthcare buyouts including medspa add-ons, confirming that deal flow continues. But the multiples have stratified sharply. A standalone medspa with $1–3M EBITDA, a single owner-operator, and flat growth is seeing 3.0–5.0x EBITDA. The same practice with multiple providers, 15%+ growth, and a membership-based recurring revenue model? 7.0–9.0x. The gap is wider than it's ever been.
In 2022, compliance issues were disclosure items — they'd lower your multiple by a turn or two, but buyers would still close. In 2026, compliance issues are deal-killers. Peptide grey-market sourcing, unlicensed staff performing injections without proper supervision, lack of documented adverse reaction protocols, unverified product sourcing — any of these will cause a sophisticated buyer to walk. Not discount. Walk.
The value drivers that matter now: owner independence (can the practice run without you?), recurring revenue (membership programs add 0.5–1.0x to your multiple), clean compliance (no warning letters, no grey-market history), and provider depth (multiple injectors/practitioners, not a single-point-of-failure).
PE firms conducting due diligence increasingly check third-party directory listings as a proxy for operational maturity. A complete, verified profile on a curated directory like GlowRoute signals to acquirers that a clinic takes its public-facing credibility seriously — the same way a well-maintained Google Business Profile does. It's a small signal, but it shows up in diligence reports.
U.S. spending on GLP-1 receptor agonists has grown at a pace almost without precedent in pharmaceutical history. The trajectory tells you everything about the size of the opportunity — and the regulatory stakes when things go wrong.
Every data point in this report distills into specific actions you can take this quarter. Here's what the most forward-thinking clinics are prioritizing — organized by role.
Review every service line against current FDA and state requirements. Document your supply chain, verify every practitioner credential, and ensure your adverse reaction protocols are written and accessible. When SB 282-style legislation hits your state, you want to be ready — not scrambling.
Recurring revenue is the single most impactful lever for both daily operations and long-term valuation. If you don't have a membership model, start one this quarter. If you do, measure retention and optimize pricing. Target: 30%+ of revenue from memberships by Q4.
Ensure your clinic data is structured and indexed across directories, Google Business Profile, and your own website. Treat your GlowRoute listing and GBP as equal priorities to your website — AI agents pull from structured sources first.
If you're still sourcing compounded semaglutide, stop. Transition patients to FDA-approved alternatives with documented prescriptions and named pharmacy suppliers. The enforcement wave is accelerating — 30 warning letters dropped in a single day in March.
The Sun Sentinel investigation made "Master Injector" a punchline. Differentiate yourself by prominently displaying your actual license type (PA, NP, RN, MD), continuing education, and supervision structure. Make it easy for patients to verify you.
When formal reclassification hits (estimated Q2), patient demand for peptide consultations will spike. Study the returning peptides, understand the 503A compounding framework, and be ready to educate patients on what Category 1 actually means.
Ensure your practice has written adverse reaction protocols, epinephrine and hyaluronidase on hand, and a clear chain of command for emergency situations. When patients ask — and they will — you should be able to answer immediately.
Review volume and quality are the #2 ranking factor for local search (behind GBP optimization). Ask every satisfied patient for a review. Before-and-after photos, with consent, are the most powerful trust signals in aesthetics marketing.
GlowRoute is building the verified, compliance-aware clinic directory for the aesthetics industry. Here's what we're seeing across the network this quarter.
The fastest-growing search categories on GlowRoute this quarter: GLP-1 clinics (driven by compounding enforcement), peptide therapy (driven by reclassification anticipation), and Botox safety verification (driven by the Sun Sentinel investigation). Patient behavior is confirming what the data says: trust, compliance, and transparency are the new competitive moat.
List Your Clinic on GlowRoute[25]
Every metric in this report is sourced. We believe transparency in reporting builds the same trust we ask clinics to build with patients. Here are the primary sources, organized by category — each is a backlink to the original material.